EN
HI

Neuland Laboratories Share price

NEULANDLAB

HealthcareLarge

11503

273.00 (2.43%)
NSE
BSE
Last updated on 30 May, 2025 | 15:54 IST
BUYSELL
Today's High

11556.00

Today's Low

11255.00

52 Week Low

5540.10

52 Week High

18100.00

The current prices are delayed, login to your account for live prices

Neuland Laboratories Chart

Neuland Laboratories Share Key Metrics

Volume
41539.00
Market Cap
14758.22 CR
LTQ@LTP
1@11503.00
ATP
11433.21
Var Margin
26.49 %
Circuit Range
8984-13476
Delivery %
49.71 %
Value
47.49 CR
ASM/GSM
No
Market Lot
1

Neuland Laboratories Futures & Options

Data Not Found

Neuland Laboratories Corporate Actions

DateAgenda
2025-07-30-
2025-05-15Audited Results & Final Dividend
2025-02-10Quarterly Results
DateEvent TypeAgenda
2025-07-30AGM/EGM-
2025-05-15Board MeetingAudited Results & Final Dividend
2025-02-10Board MeetingQuarterly Results

Neuland Laboratories News

Neuland Laboratories shares crack 7% after likely 3.8% stake offloaded via block deal

Dec 12 2024 11:56:54
Read More

About Neuland Laboratories

NSE : 2406  
BSE : 524558  
ISIN : INE794A01010  

Neuland Laboratories Limited engaged in the manufacture ofbulk drugs has been incorporated in 1984 as a privatelimited company. The Company has been promoted by Dr. D.R.Rao Ph D. in Organic Chemistry from the Universityof Notre Dame USA. The company commenced operations inJune 1986 at its plant at Bonthapally Village MedakDistrict Andhra Pradesh with a capacity to manufacture 1.2tonnes per annum (tpa) of Salbutamol sulphate an antiasthmatic drug and its intermediates such as salbutamolbase and bencyl salbutamol.In 1990 the Company expanded its installed capacity forsalbutamol sulphate and its intermediates to 9 tpa. In1993 the Company completed a project for the manufactureof 2.4 tpa of terbutaline sulphate (Terbutaline) an antiasthmatic drug 3.6 tpa of labetalol hydrochloride(Labetalol) an anti hypertension drug and for furtherexpanding the capacity of salbutamol sulphate to 18 tpa.The Company commenced manufacturing ciprofloxacin byutilising part of the additional facilities created forsalbutamol sulphate. The total project cost of Rs.346 lacswas financed by a rupee term loan of Rs.260 lacs from ICICIand cash accruals of Rs. 86 lacs.In 1994 the Company completed a project for furtherdiversifying its bulk drug manufacture and set up a newplant at I.D.A. Pashamylaram Medak district AndhraPradesh for the manufacture of 1.5 tpa of enalapril maleate(Enalapril) a cardio-vascular drug 60 tpa of ranitidinehydrochloride (Ranitidine) an anti-ulcer drug and 66 tpaof Quinolones (such as Ciprofloxacin NorfloxacinOfloxacin and Pefloxacin) a new generation ofanti-bacterial drugs. The project cost of Rs.1570 lacs wasfinanced by rupee term loans of Rs. 600 lacs (ICICI - 400SCICI - 200) equity issue of Rs. 870 lacs state subsidyof Rs. 15 lacs and cash accruals of Rs. 85 lacs. Thecommercial production commenced in October 1994. Out of theequity of Rs. 870 lacs Rs 570 lacs was offered to thepublic (at a premium of Rs 35/- per share). The issue wasoversubscribed 70 times and the shares are listed on theHyderabad and Bombay Stock Exchanges.The Company has been granted quality system certificationas per ISO 9002-9004 for its Plant at Bonthapally Villagefor the manufacture and supply of bulk drugs andintermediates.The Company has well equipped Research & Developmentfacilities at Bonthapally which has been recognised by theGovernment of India. The company''s R&D department isheaded by Dr. C. Sankar Rao who has over 31 yearsexperience in drug and pharmaceutical R&D including 25years in Indian Drugs and Pharmaceuticals Ltd. (IDPL).The Company had entered into an agreement with IndianInstitute of Chemical Technology (IICT) Hyderabad forprocess know-how for the manufacture of 2 of its productsKetorolac Tromethamine and Enalapril Maleate on 2nd December 1992.Neuland Drugs & Pharmaceuticals Private Limited (NDPL) acompany set up by the promoters to manufacture bulk drugswas incorporated in 1988 and merged with NeulandLaboratories Limited with effect from April 1 1992 as perthe Scheme of Amalgamation approved by the High Court ofAndhra Pradesh on April 6 1993. As per the scheme onefully paid up equity share in Neuland Laboratories Limitedwas exchanged for every seven fully paid up equity sharesheld in NDPL ranking pari-passu with the existing sharesof Neuland.

Neuland Laboratories Management

NamePosition
Dr. Davuluri Rama Mohan Rao Executive Chairman
Mr. Davuluri Sucheth Rao Vice Chairman & CEO
Mr. Davuluri Saharsh Rao Vice Chairman & Mng.Director
Dr. Christopher M Cimarusti Non Executive Director
Dr. Nirmala Murthy Independent Director
Read More

Neuland Laboratories FAQs

The Buying Price of Neuland Laboratories share is 11503 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Neuland Laboratories share log in to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of Neuland Laboratories shares is 56.73. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Neuland Laboratories shares is 9.68. Useful to assess the stock's value relative to its book value.

To assess Neuland Laboratories’s valuation compare Sector P/E, P/B which are 37.05 & 4.02 with sector averages, along with growth rates and financial metrics.

The Market Cap of Neuland Laboratories is 14758.22 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Neuland Laboratories share price is 18100.00 & 5540.10. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.